Browse RLN2

Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00049 Insulin/IGF/Relaxin family
Function

Relaxin is an ovarian hormone that acts with estrogen to produce dilatation of the birth canal in many mammals. May be involved in remodeling of connective tissues during pregnancy, promoting growth of pubic ligaments and ripening of the cervix.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0007565 female pregnancy
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0044706 multi-multicellular organism process
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0048514 blood vessel morphogenesis
GO:0052652 cyclic purine nucleotide metabolic process
GO:0072522 purine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901342 regulation of vasculature development
GO:1904018 positive regulation of vasculature development
Molecular Function GO:0005179 hormone activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418555: G alpha (s) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-444821: Relaxin receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RLN2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RLN2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RLN2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5960.0381
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0030.0588
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2970.511
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1450.858
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4320.747
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2110.887
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3960.589
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4180.721
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.9730.528
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1240.867
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.8250.381
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6240.00828
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RLN2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RLN2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RLN2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RLN2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RLN2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RLN2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RLN2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRLN2
Namerelaxin 2
Aliases RLXH2; bA12D24.1.1; bA12D24.1.2; relaxin H2; prorelaxin H2; relaxin, ovarian, of pregnancy; relaxin 2 (H2); ......
Chromosomal Location9p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RLN2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.